SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses a press release issued on June 3, 2026 regarding "sales and earnings results for the first quarter ended May 2, 2026," which is a standard quarterly earnings disclosure. The press release is attached as Exhibit 99.1 and furnished under Item 2.02, the standard Item for results of operations and financial condition. This is a material event affecting investor assessment of the company's financial performance.
View raw filing on EDGAR →The disclosure describes the consummation of a $150 million IPO and concurrent $3.45 million private placement by a SPAC (special purpose acquisition company), with proceeds placed in trust. While this is a material capital-raising event affecting the registrant's financial position, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or dilutive issuance in the traditional sense). SPACs are structured differently from operating companies, and the IPO itself is the primary business event rather than a subsequent equity issuance.
View raw filing on EDGAR →The filing discloses both a departure (Joseph Kimmell's retirement as EVP Operations effective June 26, 2026) and three executive appointments (Wade Lyall as Chief Sales Officer, John Kastanek as Chief Customer Experience Officer, and Andrew Houser as Senior Vice President of Manufacturing, all effective June 2, 2026). While both events are disclosed, the appointments of three officers to key operational roles represent the principal forward-looking action and structural change to the company's leadership. The departure is addressed through a consulting transition arrangement, making the appointments the more salient event.
View raw filing on EDGAR →Dorman Products entered into a purchase agreement on June 2, 2026, to issue $450 million in 6.250% Senior Notes due 2034 in a private placement to qualified institutional buyers under Rule 144A and Regulation S. While this is technically a debt issuance rather than an equity issuance, the $450 million principal amount represents a material financing event that increases the company's financial obligations and is disclosed under Item 8.01 as a significant corporate transaction. The proceeds are intended to repay existing credit facilities and fund general corporate purposes, making this a material event affecting the registrant's capital structure and financial position.
View raw filing on EDGAR →Luke A. Hewko was appointed as Chief Financial Officer of GEN Restaurant Group, Inc., effective June 1, 2026, succeeding retiring CFO Thomas V. Croal. The appointment includes a base salary of $300,000 and represents an orderly succession in the CFO role.
View raw filing on EDGAR →The Company entered into a Sales Agreement with ten underwriting agents to offer and sell up to $500 million in Class A common stock through an at-the-market (ATM) offering under an effective S-3 registration statement. This is a material dilutive equity issuance that would significantly affect shareholder ownership and the total mix of information available to investors regarding capital structure and potential dilution.
View raw filing on EDGAR →IDEAYA announced a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) in combination with RG6505 (pan-RAS inhibitor) in MTAP-deleted pancreatic cancer. This represents a material strategic partnership with a major pharmaceutical company that advances the Company's clinical development pipeline and validates its lead compound in a combination setting. While this does not fit neatly into the more specific event categories (it is not M&A, litigation, impairment, or a traditional earnings/executive event), the collaboration with Roche and the planned Phase 1 combination cohorts constitute material developments affecting the Company's business prospects and investor assessment.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Odyssey Marine Exploration's Annual Meeting of Stockholders held on June 1, 2026, including voting outcomes on director elections, auditor ratification, articles amendment, stock incentive plan increase, reverse stock split, and executive compensation approval. The filing presents detailed vote tallies for each proposal, which is the core purpose of Item 5.07 shareholder vote results disclosures. The reverse stock split and authorized share increase are material corporate actions requiring shareholder approval.
View raw filing on EDGAR →Worthington Steel completed a material acquisition of Klöckner shares, acquiring 52,389,508 shares at €11.00 per share (€576.3 million aggregate consideration) and bringing total ownership to approximately 60.86% of Klöckner's outstanding share capital. The acquisition was funded through notes offerings and term loan borrowing.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Viridian Therapeutics' 2026 Annual Meeting of Stockholders held on June 2, 2026, including election of two Class II directors (Tomas Kiselak and Jennifer K. Moses), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and determination of advisory vote frequency (annually). The tabulated vote counts and board determination constitute a standard shareholder vote results disclosure material to investors' understanding of governance and management approval.
View raw filing on EDGAR →The filing explicitly discloses financial results for the quarter ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides the registrant's periodic financial performance.
View raw filing on EDGAR →The filing discloses the Company's operating results for the first quarter of fiscal 2026 via a press release furnished as Exhibit 99.1, with an accompanying investor webcast. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →The filing discloses an update on a merger with FBB Holdings I, Inc., which constitutes material acquisition activity. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01 or 2.01, the substance is a merger update that would materially affect investor assessment of the registrant's strategic direction and capital structure.
View raw filing on EDGAR →REGENXBIO held its 2026 Annual Meeting of Shareholders on May 29, 2026, with final voting results disclosed for five proposals: election of three Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, approval of a stock option exchange program for non-executive employees, and rejection of a stock option exchange program for executive employees.
View raw filing on EDGAR →REGENXBIO commenced a shareholder-approved Stock Option Exchange Program permitting non-executive employees to exchange underwater stock options with an exercise price of $18.00 or greater for new options granted at fair market value, affecting the company's equity incentive structure.
View raw filing on EDGAR →Dyne Therapeutics announced full enrollment of the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1 patients, with 71 participants enrolled. The company disclosed material clinical development milestones including planned topline data in Q1 2027 and potential BLA submission for Accelerated Approval in Q3 2027, representing significant progress for its lead program.
View raw filing on EDGAR →NewAmsterdam Pharma held its Annual General Meeting on June 2, 2026, at which shareholders voted on nine proposals including adoption of annual accounts, director discharge, auditor appointment, director re-appointments, share issuance authorization, and executive compensation approval.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Byline Bancorp's annual stockholder meeting held on June 2, 2026. The filing presents detailed voting results for five proposals: election of ten directors, advisory vote on named executive officer compensation, approval of the 2026 Omnibus Incentive Compensation Plan, amendment to the Employee Stock Purchase Plan, and ratification of Baker Tilly US, LLP as independent auditor. All proposals passed with substantial majorities, and the disclosure includes vote counts and broker non-votes for each proposal, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →Western Digital entered into exchange agreements to retire approximately $858.4 million in convertible notes through a combination of cash and equity issuance (Exchange Shares), relying on Section 4(a)(2) exemption for the unregistered sale of equity securities.
View raw filing on EDGAR →This disclosure concerns a material qui tam lawsuit filed by a former employee against Corcept in February 2017 alleging improper sales and promotion practices related to Korlym®, with DOJ investigation (subpoena issued November 2021) and an amended complaint served June 2, 2026. The DOJ's declination to intervene does not eliminate the litigation risk; the Relator proceeds independently. This is a material regulatory/litigation matter affecting the company's legal exposure and product reputation.
View raw filing on EDGAR →Cardiff Oncology disclosed Phase 2 CRDF-004 clinical trial data and registrational study plans for onvansertib via an investor presentation under Regulation FD. While this represents material clinical development information that would affect investor assessment of the company's pipeline and regulatory pathway, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, executive change, or other specifically defined event). The disclosure is material because clinical trial results and regulatory strategy are central to a biotech company's valuation and investor decision-making.
View raw filing on EDGAR →ATI Inc. announced its intention to conduct an underwritten public offering of seven-year senior notes. While this is a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit neatly into the more specific categories (dilutive_issuance applies to equity, not debt; ma_activity covers acquisitions/dispositions). The disclosure is material but represents a debt financing announcement rather than a discrete event type in the taxonomy.
View raw filing on EDGAR →The filing discloses settlement of patent litigation involving SUNOSI® (solriamfetol), a key product for Axsome Therapeutics. Patent litigation settlements can materially affect product exclusivity, market access, and competitive positioning. The press release title explicitly references "Settlement Resolving All SUNOSI® Patent Litigation," indicating comprehensive resolution of patent disputes that would be material to investors assessing the company's intellectual property protection and commercial prospects.
View raw filing on EDGAR →CECONY entered into an underwriting agreement on June 1, 2026 to issue $1.3 billion in aggregate principal amount of debentures ($450 million 5.15% due 2036 and $850 million 5.875% due 2056). While this is a material debt issuance affecting the registrant's capital structure and financial position, it does not fit the specific taxonomy categories: it is not a dilutive equity issuance (Item 3.02), not a material acquisition or disposition (Item 1.01/2.01), and not a restatement, auditor change, or other enumerated event. The disclosure is material to investors as it represents a significant financing activity, but the most appropriate classification is other_material given the absence of a dedicated debt issuance category.
View raw filing on EDGAR →The filing discloses an unregistered sale of 439,785.519 common shares of beneficial interest for approximately $8.9 million under Section 4(a)(2) and Regulation D. This is a classic dilutive private placement of equity securities exempt from registration, which materially increases the share count and affects existing shareholders' ownership percentages. The Item 3.02 designation and detailed breakdown of Class S and Class I shares sold confirm this is a reportable unregistered equity issuance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Comstock Resources' Annual Meeting held June 2, 2026. The filing presents detailed voting results for three proposals: re-election of five board directors (all passed with strong majorities), ratification of Ernst & Young LLP as independent auditor (passed with 99.8% support), and advisory approval of 2025 named executive officer compensation (passed with 99.8% support). The disclosure is material as shareholder votes on board composition, auditor appointment, and executive compensation directly affect investor assessment of corporate governance and management accountability.
View raw filing on EDGAR →PIMCO Asset-Based Lending Company LLC issued and sold unregistered limited liability company interests across multiple classes to third-party investors for aggregate consideration of approximately $67.8 million on May 1, 2026, pursuant to Section 4(a)(2) and Regulations D and S exemptions.
View raw filing on EDGAR →The Company issued 21,257 shares of Class X-1 common stock in a private placement to an accredited investor for $500,000, relying on Section 4(a)(2) and Regulation D Rule 506(c) exemptions from registration. This is a classic unregistered equity issuance disclosed under Item 3.02, representing dilutive capital raising activity that would materially affect investor assessment of share ownership and capitalization.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Watsco's 2026 Annual Meeting held on June 1, 2026, filed under Item 5.07. The filing presents final voting tallies for three proposals: (1) election of directors (Ana Lopez-Blazquez for Common stock, Cesar L. Alvarez and Denise Dickins for Class B stock), (2) advisory vote on named executive officer compensation, and (3) ratification of Deloitte & Touche LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →Xenon Pharmaceuticals held its Annual Meeting of shareholders on June 2, 2026, with voting results on six proposals including election of eight directors, advisory say-on-pay approval, say-on-pay frequency (1-year), approval of the 2026 Equity Incentive Plan, appointment of PricewaterhouseCoopers LLP as auditor, and auditor remuneration authority. All proposals passed with strong shareholder majorities.
View raw filing on EDGAR →On June 1, 2026, stockholders voted at the annual meeting on four proposals: election of nine directors, approval of the Second Amended and Restated 2020 Stock Incentive Plan (increasing available shares from 2,900,000 to 4,100,000), an advisory vote on named executive officer compensation, and ratification of Deloitte and Touche LLP as independent auditor. Detailed vote tallies for each proposal are disclosed.
View raw filing on EDGAR →The disclosure centers on the Human Capital Committee's approval of a 500,000 restricted stock unit grant to Sean Mackay, Chief Business Officer, under the 2026 Equity Incentive Plan with a two-year vesting schedule (40% in 2027, 60% in 2028). This is a compensatory arrangement for a named executive officer and falls squarely within exec_compensation. The grant is material as it represents a significant equity award to a senior officer.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports final vote tallies for two proposals: election of two Class I directors (Niall Casey and Philip Young) and ratification of Ernst & Young LLP as independent auditor. This is a textbook shareholder_vote_results event under Item 5.07, and the outcomes are material to investors as they determine board composition and auditor selection.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the 2026 annual meeting of stockholders held on June 3, 2026. The filing presents voting results for three proposals: (1) election of director Brian D. Dunn, (2) advisory approval of executive compensation, and (3) ratification of Deloitte & Touche LLP as independent auditor. These are routine annual meeting matters with clear vote tallies, making this unambiguously a shareholder_vote_results event.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Shimmick Corporation's 2026 Annual Meeting held on June 2, 2026. The filing reports the final voting tallies for two proposals: (1) election of five directors for one-year terms, and (2) ratification of Deloitte & Touche LLP as independent auditor. All directors were elected with substantial majorities, and the auditor appointment was ratified with overwhelming support. This is material as it confirms the composition of the board and auditor for the upcoming fiscal year.
View raw filing on EDGAR →DBV Technologies held its Annual Combined Meeting of Shareholders on June 3, 2026, with voting results on 39 proposals including financial statement approvals, director elections and renewals, executive compensation approvals, and various delegations of authority to the Board.
View raw filing on EDGAR →Fifth Third Bancorp voluntarily transferred its principal listing from Nasdaq to the NYSE, effective June 11-12, 2026. This material corporate action affects the regulatory framework and trading mechanics for the company's securities.
View raw filing on EDGAR →The Audit Committee dismissed PricewaterhouseCoopers LLP as the independent registered public accounting firm and appointed KPMG LLP as the new auditor for fiscal year 2027. This is a direct auditor change disclosed under Item 4.01. The filing confirms no disagreements or reportable events with the prior auditor, indicating a routine transition rather than a conflict-driven change. Auditor changes are material to investors as they affect financial statement reliability and oversight.
View raw filing on EDGAR →Netskope disclosed financial results for the first quarter of fiscal 2027 ended April 30, 2026, via a press release furnished as Exhibit 99.1, including reconciliation of non-GAAP measures to GAAP comparables.
View raw filing on EDGAR →Andrew Del Matto, Chief Financial Officer, announced his retirement effective upon the start of a successor, with the company conducting a search and Del Matto remaining during the transition period.
View raw filing on EDGAR →FONAR Corp completed a merger transaction in which all outstanding shares were converted into fixed cash consideration ($19.00 per Common/Class B share, $6.34 per Class C share, $10.50 per Class A Non-voting Preferred share), with the Company becoming a wholly owned subsidiary of Parent. The transaction included a $35 million credit facility ($20M term loan + $15M revolver) secured by substantially all assets of the borrowers and guarantors.
View raw filing on EDGAR →Four directors—Ronald G. Lehman II, Richard E. Turk, Jessica Maher, and Robert M. Carrino—resigned from the board effective at the Effective Time of the merger, with the company noting the resignations were not due to any disagreement.
View raw filing on EDGAR →FONAR notified Nasdaq of its intent to remove the Common Stock from listing, requested suspension of trading prior to June 3, 2026, and intends to file a Form 25 to delist and deregister the Common Stock under Section 12(b) of the Exchange Act, as well as a Form 15 to suspend reporting obligations.
View raw filing on EDGAR →FONAR amended and restated its Certificate of Incorporation effective at the Effective Time of the merger, and modified security holder rights in connection with the transaction.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Macerich's annual stockholder meeting held June 1, 2026. The filing presents voting results for three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. The detailed vote tallies (For, Against, Abstentions, Broker non-Votes) for each proposal are the core content, making this unambiguously a shareholder vote results disclosure that is material to investors assessing board composition and governance.
View raw filing on EDGAR →CytomX entered into Amendment No. 4 to its existing Collaboration and License Agreement with Regeneron on May 29, 2026, which materially expands the scope of the collaboration by extending the program selection period and adding up to eight additional collaboration programs with total potential payments and milestones of approximately $4 billion. The amendment includes immediate nomination payments of $37.0 million for the first two programs, representing a material modification to an existing material agreement that would affect investor assessment of the company's revenue prospects and partnership value.
View raw filing on EDGAR →Stockholders approved three proposals at a Special Meeting held in May 2026: (1) issuance of warrants in connection with a licensing transaction and private placement, (2) adoption of the 2026 Stock Incentive Plan, and (3) adjournment of the meeting if necessary.
View raw filing on EDGAR →PG&E completed a $2.2 billion debt issuance of First Mortgage Bonds across three tranches (2031, 2036, and 2056 maturities) on June 3, 2026. While material financing activity, this does not fit the specific taxonomy categories: it is not M&A, not a dilutive equity issuance, and not a covenant breach or going-concern disclosure. The disclosure is material to investors as it reflects the company's capital structure and financing strategy, but the 8-K Item 8.01 treatment and the nature of the transaction (routine debt financing for a regulated utility) suggest classification as other_material rather than a more specific event type.
View raw filing on EDGAR →Cerus Corp held its 2026 Annual Meeting of Stockholders on June 2, 2026, with voting results on four proposals: election of directors William M. Greenman and Ann Lucena, approval of an amended 2024 Equity Incentive Plan with 10 million additional shares, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →This disclosure describes entry into a dealer manager agreement for distribution of fund units and shares, with a servicing fee structure of up to 0.85% of NAV per annum. While Item 1.01 typically covers M&A activity, this agreement is a material definitive agreement governing the fund's distribution infrastructure and fee arrangements. The agreement is material to investors as it establishes the economic terms and distribution mechanism for the fund's securities, but does not fit cleanly into the M&A taxonomy (no acquisition, merger, or change of control is occurring).
View raw filing on EDGAR →